Candela Announces FDA Clearance for Psoriasis Device
WAYLAND, Mass., Jan 25, 2001 (BUSINESS WIRE) -- Candela Corporation (NASDAQ: CLZR chart, msgs) announced today that it had received clearance from the U.S. Food and Drug Administration to market a laser for the treatment of psoriasis. The Company said it is conducting on-going clinical trials and expects to market the device this coming summer.
Gerard E. Puorro, Candela's President & Chief Executive Officer commented: "Following acne, psoriasis is the second most common skin disorder in the United States. The market is underserved by current treatments. We are excited to be able to play a role in such a market." Puorro added: "While we won't market this device before summer, we are announcing this now to clarify the timing of our entry."
About Candela: Candela Corporation develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 50 countries from offices in the United States, Europe, Japan and Asia. Candela established the aesthetic laser market 12 years ago, and currently has an installed base of over 4,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer, M/F/H/V. Visit Candela on the Web at www.clzr.com.
Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future which are, therefore, inherently subject to risks and uncertainties. Candela's actual results could differ materially from those anticipated in Candela's forward-looking statements based on various factors, including without limitation: cancellation or deferral of customer orders, total dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, or changes in economic conditions. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Form 10-K (or any amendment thereto) for the year ended July 1, 2000, and subsequent Forms 10-Q. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstance on which any such statement is based.
Contact:
Candela Corporation
Jane Smith
508-358-7400 x 247
or
Luise Cahill, Seidler Bernstein
781-235-2782 |
